The anti-B-cell maturation antigen BiTE molecule AMG 420 was assessed in patients with relapsed/refractory multiple myeloma.In this first-in-human study, up to 10 cycles of AMG 420 were given (4-week infusions/6-week […]
Recent Content
- (no title)
- (no title)
- Trial offers ‘a light’ for patients with extramedullary myeloma
- Expanding access to care in multiple myeloma
- (no title)
- Vyriad targets 2026 clinical trial for new experimental cell therapy VV169
- Structured whole-body MRI highlights clinically relevant disease pattern changes in relapsed/refractory multiple myeloma
- Secondary malignancy of T-cell origin after CAR T-cell therapy: EMA’s conclusions from the evaluation of 38 suspected cases
- Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma
- (no title)